Atomoxetine (Strattera)
Non-stimulant medication for Attention Deficit Hyperactivity Disorder (ADHD)
Atomoxetine is a non-stimulant medication used to treat Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 years and older, adolescents, and adults. Unlike stimulant ADHD medications, atomoxetine works by selectively inhibiting the reuptake of norepinephrine in the brain, which improves attention, reduces impulsivity, and decreases hyperactivity. It is not a controlled substance and has no known abuse potential, making it a preferred option when stimulant medications are not suitable.
Quick Facts
Key Takeaways
- Atomoxetine is the first non-stimulant medication approved for ADHD treatment, with no abuse or dependence potential
- It works by increasing norepinephrine levels in the brain, improving attention and reducing impulsivity over several weeks
- Approved for children aged 6 and older, adolescents, and adults, as part of a comprehensive ADHD treatment program
- Must not be taken with MAO inhibitors or by patients with narrow-angle glaucoma, pheochromocytoma, or severe cardiovascular conditions
- Requires monitoring for suicidal thoughts (especially in young people), cardiovascular effects, and rare liver injury
What Is Atomoxetine and What Is It Used For?
Quick Answer: Atomoxetine is a selective norepinephrine reuptake inhibitor (NRI) used to treat ADHD in children, adolescents, and adults. It is the first non-stimulant medication specifically developed for ADHD and is not a controlled substance.
Atomoxetine, sold under the brand name Strattera and various generic versions, is a prescription medication that belongs to a class of drugs known as selective norepinephrine reuptake inhibitors. It was the first non-stimulant medication to receive approval from major regulatory agencies, including the FDA and EMA, for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). This distinguishes it from traditional ADHD medications like methylphenidate and amphetamines, which are central nervous system stimulants.
The medication works by selectively blocking the norepinephrine transporter in the brain. Norepinephrine is a naturally occurring neurotransmitter that plays a critical role in attention, arousal, and executive function. By preventing the reuptake of norepinephrine back into nerve cells, atomoxetine increases the availability of this neurotransmitter in the synaptic cleft, particularly in the prefrontal cortex—the brain region most implicated in ADHD. This mechanism of action leads to improved attention span, reduced impulsivity, and decreased hyperactivity in patients with ADHD.
Atomoxetine is approved for use in children from 6 years of age, adolescents, and adults. It is always prescribed as part of a comprehensive treatment program that may include psychological, educational, and social interventions such as counseling and behavioral therapy. The medication is not indicated for children under 6 years of age, as its safety and efficacy have not been established in this age group.
In adults, atomoxetine is used when ADHD symptoms are significantly impairing work, education, or social functioning, and when there is evidence that symptoms were present during childhood. Because atomoxetine does not act on the dopamine reward pathway in the same way as stimulant medications, it has no significant abuse potential and is not classified as a controlled substance. This makes it a valuable alternative for patients who have a history of substance use disorders or for whom stimulant medications are contraindicated.
How Does Atomoxetine Work?
Unlike stimulant ADHD medications that primarily increase dopamine activity, atomoxetine works through a different pharmacological mechanism. It selectively inhibits the presynaptic norepinephrine transporter, leading to increased norepinephrine concentrations in the brain. Research has shown that this mechanism also indirectly increases dopamine levels specifically in the prefrontal cortex (where dopamine reuptake is primarily handled by the norepinephrine transporter), without significantly affecting dopamine levels in the nucleus accumbens or striatum—brain regions associated with reward and addiction.
It is important to understand that atomoxetine does not produce the immediate effects seen with stimulant medications. The therapeutic benefits develop gradually, typically over a period of several weeks. Most patients begin to notice some improvement within 1 to 2 weeks, but the full therapeutic effect is generally achieved after 4 to 6 weeks of treatment at an appropriate dose. This gradual onset is consistent with its mechanism as a reuptake inhibitor and distinguishes it from the more rapid-acting stimulant alternatives.
About ADHD
ADHD is one of the most common neurodevelopmental disorders, affecting approximately 5-7% of children and 2.5-4% of adults worldwide, according to epidemiological data published in The Lancet and endorsed by the World Health Organization. The condition is characterized by persistent patterns of inattention, hyperactivity, and impulsivity that interfere with functioning and development.
Children and adolescents with ADHD may find it difficult to sit still, pay attention in class, complete homework, and follow instructions. These difficulties are not a reflection of intelligence or effort—ADHD is a neurobiological condition. Adults with ADHD often experience challenges with organization, time management, maintaining employment, sustaining relationships, and may struggle with low self-esteem and emotional regulation.
What Should You Know Before Taking Atomoxetine?
Quick Answer: Atomoxetine must not be taken with MAO inhibitors, or by individuals with narrow-angle glaucoma, pheochromocytoma, or severe cardiovascular disease. Discuss your full medical history with your doctor before starting treatment.
Contraindications
There are several situations in which atomoxetine must not be used. These absolute contraindications are based on the potential for serious or life-threatening adverse effects:
- Allergy to atomoxetine or any of the inactive ingredients in the formulation
- MAO inhibitors: Do not take atomoxetine if you have used a monoamine oxidase inhibitor (MAOI) such as phenelzine, tranylcypromine, or selegiline within the past 14 days. Combining these medications can cause a dangerous and potentially fatal interaction. After stopping atomoxetine, wait at least 14 days before starting an MAOI.
- Narrow-angle glaucoma: Atomoxetine may increase intraocular pressure and should not be used in patients with this condition
- Severe cardiovascular conditions: Including serious heart defects, heart failure, cardiomyopathy, or conditions that may be worsened by increases in heart rate or blood pressure
- Cerebrovascular disease: Including history of stroke, cerebral aneurysm, or significant vascular narrowing or blockage
- Pheochromocytoma: A tumor of the adrenal gland that produces excess catecholamines
Never take atomoxetine together with, or within 14 days of stopping, an MAO inhibitor. This combination can cause dangerous increases in blood pressure and potentially fatal serotonin-like reactions. Similarly, wait at least 14 days after stopping atomoxetine before starting an MAOI.
Warnings and Precautions
Before starting atomoxetine, inform your doctor if you have any of the following conditions, as additional monitoring or dose adjustments may be necessary:
- Suicidal thoughts or behavior: Atomoxetine carries a regulatory warning about an increased risk of suicidal thinking in children and adolescents. Close monitoring is essential, especially during the first months of treatment or when the dose is changed.
- Heart problems: Including heart defects, irregular heartbeat, or rapid heart rate. Atomoxetine can increase heart rate and blood pressure. Sudden death has been reported in rare cases among patients with pre-existing structural cardiac abnormalities.
- High blood pressure: The medication may cause further elevation of blood pressure
- Low blood pressure: Atomoxetine may cause dizziness or fainting in individuals with hypotension
- Cardiovascular or cerebrovascular disease: Including history of heart attack or stroke
- Liver problems: Patients with hepatic impairment may require dose reduction. Rare cases of serious liver injury, including liver failure, have been reported.
- Psychiatric conditions: Including psychosis, mania, hallucinations, aggressive behavior, hostility, or mood instability
- Seizure disorders: Atomoxetine may potentially lower the seizure threshold
- Tics or Tourette syndrome: The medication may exacerbate involuntary movements or vocalizations
Before starting atomoxetine, your doctor should measure your blood pressure and heart rate (these will be monitored throughout treatment), assess your height and weight (in children and adolescents), review your family medical history for cardiovascular conditions or sudden unexplained death, evaluate any psychiatric symptoms, and discuss all other medications you are currently taking.
Serotonin Syndrome
Serotonin syndrome is a potentially life-threatening condition that can occur when atomoxetine is combined with other serotonergic medications. Although atomoxetine primarily affects norepinephrine, it has some serotonergic activity that can contribute to this syndrome when combined with certain drugs. Signs and symptoms may include confusion, agitation, muscle rigidity or twitching, rapid heartbeat, high blood pressure, excessive sweating, dilated pupils, diarrhea, and in severe cases, high fever and seizures. If you experience any combination of these symptoms, seek emergency medical attention immediately.
Aggressive Behavior and Emotional Changes
Treatment with atomoxetine may trigger or worsen feelings of aggression, hostility, or emotional instability. Some patients have experienced unusual changes in behavior or mood, including physical aggression, threatening behavior, or thoughts of harming others. If you, your family members, or caregivers notice any such changes, contact your doctor immediately. These effects should be carefully weighed against the therapeutic benefits.
Pregnancy and Breastfeeding
The safety of atomoxetine during pregnancy has not been fully established. It is not known whether atomoxetine causes harm to the developing fetus. If you are pregnant, planning to become pregnant, or discover you are pregnant while taking atomoxetine, consult your doctor promptly to discuss the risks and benefits of continuing treatment.
It is not known whether atomoxetine passes into breast milk. If you are breastfeeding or planning to breastfeed, you should either discontinue the medication or stop breastfeeding, in consultation with your healthcare provider.
Driving and Operating Machinery
Atomoxetine may cause tiredness, drowsiness, or dizziness. Do not drive, use tools, or operate machinery until you know how this medication affects you. If you experience these side effects, refrain from activities requiring alertness until the effects resolve.
Capsule Handling
Do not open atomoxetine capsules, as the contents can irritate the eyes. If the capsule contents come into contact with your eyes, flush immediately with water and seek medical advice. Wash any skin that comes into contact with the capsule contents as soon as possible.
How Does Atomoxetine Interact with Other Drugs?
Quick Answer: Atomoxetine has potentially dangerous interactions with MAO inhibitors and serotonergic drugs. It is also affected by CYP2D6 inhibitors like fluoxetine and paroxetine, which can significantly increase atomoxetine blood levels.
Drug interactions with atomoxetine can alter its effectiveness or increase the risk of adverse effects. Always inform your doctor and pharmacist about all medications you are taking, including prescription drugs, over-the-counter medications, and herbal supplements. The following table summarizes the most clinically significant interactions.
Major Interactions
| Interacting Drug | Effect | Recommendation |
|---|---|---|
| MAO inhibitors (phenelzine, selegiline, tranylcypromine) | Risk of hypertensive crisis and serotonin-like reactions; potentially fatal | Absolutely contraindicated. Allow 14-day washout period between medications. |
| Fluoxetine, Paroxetine (CYP2D6 inhibitors) | Significantly increased atomoxetine blood levels (up to 6-8 fold); increased side effects | Dose reduction of atomoxetine required; close monitoring for adverse effects. |
| Quinidine, Terbinafine (CYP2D6 inhibitors) | Increased atomoxetine levels due to inhibited metabolism | Dose adjustment may be needed; monitor for side effects. |
| SSRIs, SNRIs, Triptans, Tramadol | Risk of serotonin syndrome when combined | Use with caution; monitor for serotonin syndrome symptoms. |
| Imipramine and other tricyclic antidepressants | Additive cardiovascular effects; increased risk of QT prolongation | Use with caution; cardiac monitoring recommended. |
Other Notable Interactions
| Interacting Drug | Effect | Recommendation |
|---|---|---|
| Salbutamol (oral or injectable) | May cause sensation of racing heart; does not worsen asthma | Use with awareness; inhaled salbutamol is generally safe. |
| Antihypertensive medications | Atomoxetine may counteract blood pressure lowering effects | Monitor blood pressure regularly; dose adjustments may be needed. |
| Antiarrhythmic drugs | Increased risk of abnormal heart rhythm (QT prolongation) | Avoid combination if possible; cardiac monitoring required. |
| Certain antibiotics (erythromycin, moxifloxacin) | Increased risk of QT prolongation | Use with caution; ECG monitoring may be warranted. |
| Antimalarial drugs | Potential for abnormal heart rhythm | Use with caution; discuss alternatives with your doctor. |
| Decongestants (pseudoephedrine) | May increase blood pressure | Check with pharmacist before using cold and cough products. |
Atomoxetine is primarily metabolized by the liver enzyme CYP2D6. Approximately 5-10% of Caucasians and 1-2% of Asians are "poor metabolizers" who have reduced CYP2D6 activity. In these individuals, atomoxetine levels may be significantly higher than in extensive metabolizers, requiring lower doses. Your doctor may consider genetic testing if you experience unusual side effects.
What Is the Correct Dosage of Atomoxetine?
Quick Answer: Dosing is weight-based in children under 70 kg, starting at 0.5 mg/kg/day and increasing to approximately 1.2 mg/kg/day. Adults and children over 70 kg start at 40 mg/day, with a target of 80-100 mg/day. The maximum dose is 100 mg/day.
Atomoxetine dosage is carefully individualized based on body weight, age, and clinical response. The capsules should be swallowed whole with water, with or without food. Do not open, crush, or chew the capsules. Taking atomoxetine at the same time each day helps maintain consistent blood levels and improves adherence.
Children and Adolescents (6 Years and Older)
Body weight up to 70 kg
- Starting dose: 0.5 mg/kg/day for at least 7 days
- Target maintenance dose: Approximately 1.2 mg/kg/day
- Administration: Once daily (morning) or divided into two doses (morning and late afternoon/early evening)
Body weight over 70 kg
- Starting dose: 40 mg/day for at least 7 days
- Target maintenance dose: 80 mg/day
- Maximum dose: 100 mg/day
Adults
Standard Adult Dosing
- Starting dose: 40 mg/day for at least 7 days
- Target maintenance dose: 80–100 mg/day
- Maximum dose: 100 mg/day
- Administration: Once daily in the morning, or divided into two doses (morning and late afternoon/early evening) if side effects such as nausea or fatigue occur with once-daily dosing
Dosage in Hepatic Impairment
Patients with liver problems may require a reduced dose. In moderate hepatic impairment (Child-Pugh Class B), the dose should be reduced to 50% of the normal dose. In severe hepatic impairment (Child-Pugh Class C), the dose should be reduced to 25% of the normal dose. Your doctor will determine the appropriate dose based on your liver function.
Dosage Table
| Patient Group | Starting Dose | Target Dose | Maximum Dose |
|---|---|---|---|
| Children/Adolescents ≤70 kg | 0.5 mg/kg/day | 1.2 mg/kg/day | 1.4 mg/kg/day or 100 mg |
| Children/Adolescents >70 kg | 40 mg/day | 80 mg/day | 100 mg/day |
| Adults | 40 mg/day | 80–100 mg/day | 100 mg/day |
| Hepatic impairment (moderate) | 50% of normal | 50% of normal | 50% of normal maximum |
| Hepatic impairment (severe) | 25% of normal | 25% of normal | 25% of normal maximum |
Monitoring During Treatment
Your doctor will conduct regular monitoring throughout your treatment with atomoxetine, typically at least every 6 months and whenever the dose is changed. This monitoring includes measuring height and weight in children and adolescents, checking blood pressure and heart rate, evaluating the effectiveness of treatment, and assessing for any side effects. If you have been taking atomoxetine for more than one year, your doctor will review whether continued treatment is still necessary.
Missed Dose
If you miss a dose, take it as soon as you remember. However, do not exceed the total prescribed daily dose within a 24-hour period. Never take a double dose to make up for a forgotten one.
Overdose
If you suspect an overdose, contact your local poison control center or emergency services immediately. Common symptoms of overdose include gastrointestinal disturbances (nausea, vomiting), drowsiness, dizziness, tremor, and abnormal behavior. In very rare cases, serotonin syndrome has been reported following overdose. There is no specific antidote for atomoxetine overdose; treatment is supportive and symptomatic.
What Are the Side Effects of Atomoxetine?
Quick Answer: The most common side effects include nausea, decreased appetite, headache, drowsiness, and increased heart rate/blood pressure. Serious but rare side effects include suicidal thoughts (especially in young people), liver damage, and severe allergic reactions.
Like all medications, atomoxetine can cause side effects, although not everyone experiences them. Most side effects are mild to moderate and tend to improve after the first few weeks of treatment. Your doctor will discuss the potential side effects with you and weigh them against the expected benefits. The side effect profiles differ somewhat between children/adolescents and adults.
Contact your doctor or go to the emergency department immediately if you experience: rapid or irregular heartbeat, suicidal thoughts or self-harm, severe allergic reactions (swelling of the face/throat, difficulty breathing, hives), signs of liver damage (dark urine, yellowing of skin/eyes, right-sided abdominal pain, unexplained nausea, fatigue, itching), or seizures.
Side Effects in Children and Adolescents (6 Years and Older)
Very Common
Affects more than 1 in 10 patients
- Headache
- Stomach pain (abdominal pain)
- Decreased appetite
- Nausea or vomiting
- Drowsiness (somnolence)
- Increased blood pressure
- Increased heart rate
Common
Affects 1 in 10 to 1 in 100 patients
- Irritability
- Sleep problems and early awakening
- Depression, sadness, or hopelessness
- Anxiety
- Tics (involuntary movements)
- Dilated pupils
- Dizziness
- Constipation and loss of appetite
- Skin rash, itching, or redness
- Fatigue, lethargy, and chest pain
- Weight loss
Uncommon
Affects 1 in 100 to 1 in 1,000 patients
- Fainting (syncope)
- Tremor
- Migraine and blurred vision
- Abnormal skin sensations (tingling, numbness)
- Seizures
- QT prolongation (abnormal heart rhythm)
- Shortness of breath and increased sweating
- Suicidal thoughts (higher risk in under-18s)
- Aggressive, hostile, or angry feelings
- Mood swings
- Psychotic symptoms (hallucinations, delusions)
Rare
Affects fewer than 1 in 1,000 patients
- Raynaud’s phenomenon (poor circulation causing pale, numb fingers/toes)
- Urinary problems (frequent urination, painful urination)
- Prolonged, painful erections (priapism)
- Liver damage (see warning above)
Side Effects in Adults
Very Common
Affects more than 1 in 10 patients
- Nausea
- Dry mouth
- Headache
- Decreased appetite
- Insomnia (difficulty falling asleep, staying asleep, early awakening)
- Increased blood pressure
- Increased heart rate
Common
Affects 1 in 10 to 1 in 100 patients
- Irritability and decreased libido
- Sleep disturbances and depression
- Anxiety, dizziness, and tremor
- Abnormal taste
- Tingling or numbness in hands and feet
- Drowsiness, fatigue, and lethargy
- Constipation, stomach pain, indigestion, and flatulence
- Vomiting
- Hot flashes, increased sweating
- Skin rash and palpitations
- Urinary difficulties (painful urination, prostatitis)
- Erectile dysfunction and ejaculatory difficulties
- Menstrual cramps
- Weakness, chills, and weight loss
Uncommon
Affects 1 in 100 to 1 in 1,000 patients
- Restlessness and tics
- Fainting and migraine
- Blurred vision
- QT prolongation (abnormal heart rhythm)
- Cold fingers and toes
- Chest pain, shortness of breath
- Muscle twitching
- Frequent urination, abnormal orgasm
- Irregular menstruation
Rare
Affects fewer than 1 in 1,000 patients
- Raynaud’s phenomenon
- Prolonged, painful erections (priapism)
- Seizures and psychotic symptoms (in adults: fewer than 1 in 1,000)
- Liver damage
Effects on Growth
Some children may experience a temporary slowdown in growth (height and weight) during the initial period of atomoxetine treatment. Clinical studies have shown that most children eventually reach their expected height and weight with long-term treatment. Your doctor will monitor your child’s growth regularly, and may consider temporarily discontinuing the medication or adjusting the dose if growth is significantly affected.
It is important to report any suspected side effects to your healthcare provider or national adverse drug reaction reporting system. You can also report side effects through your country’s pharmacovigilance agency (e.g., FDA MedWatch in the US, Yellow Card Scheme in the UK, or EMA EudraVigilance in the EU). Reporting helps ensure the ongoing safety monitoring of medications.
How Should You Store Atomoxetine?
Quick Answer: Store atomoxetine at or below 30°C (86°F), in its original packaging, and keep out of reach of children. Use bottle-packaged capsules within 6 months of opening.
Proper storage of atomoxetine is essential to maintain the medication’s effectiveness and safety. Follow these guidelines to ensure your medication remains in optimal condition:
- Temperature: Store at or below 30°C (86°F). Do not freeze.
- Light and moisture: Keep the capsules in their original packaging (blister pack or bottle) to protect from moisture and light.
- Bottle packaging: If your medication comes in a bottle, use the capsules within 6 months after first opening.
- Expiry date: Do not use atomoxetine after the expiry date printed on the packaging. The expiry date refers to the last day of the stated month.
- Children: Keep all medications out of the sight and reach of children.
- Disposal: Do not dispose of medications via wastewater or household waste. Return unused or expired medications to your pharmacy for safe disposal to protect the environment.
What Does Atomoxetine Contain?
Quick Answer: Each capsule contains atomoxetine hydrochloride (equivalent to 10–100 mg atomoxetine) plus inactive ingredients including pregelatinized starch, dimethicone, and gelatin capsule shell. The oral solution contains 4 mg/ml atomoxetine.
Atomoxetine is available in two formulations: hard capsules and oral solution. Understanding the composition of your medication is important, particularly if you have known allergies to any ingredients.
Active Ingredient
The active substance is atomoxetine hydrochloride. Each hard capsule contains atomoxetine hydrochloride equivalent to 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, or 100 mg of atomoxetine. The oral solution contains 4 mg/ml of atomoxetine.
Inactive Ingredients (Capsules)
- Capsule contents: Pregelatinized maize starch, dimethicone 350 cs, sodium starch glycolate (Type A)
- Capsule shell: Gelatin, titanium dioxide (E171), printing ink (shellac, propylene glycol, ammonia, black iron oxide E172, potassium hydroxide)
- Colorants (vary by strength): Yellow iron oxide (E172), indigocarmine (E132), red iron oxide (E172), and black iron oxide (E172)
This medication contains less than 1 mmol (23 mg) sodium per capsule, meaning it is essentially sodium-free. This information is relevant for patients on a sodium-restricted diet.
Available Capsule Strengths and Identification
| Strength | Appearance | Size |
|---|---|---|
| 10 mg | Opaque white | Size 4 (14.3 mm) |
| 18 mg | Gold cap / white body | Size 3 (15.9 mm) |
| 25 mg | Blue cap / white body | Size 3 (15.9 mm) |
| 40 mg | Opaque blue | Size 2 (18 mm) |
| 60 mg | Blue cap / gold body | Size 2 (18 mm) |
| 80 mg | Brown cap / white body | Size 1 (19.4 mm) |
| 100 mg | Opaque brown | Size 0 (21.7 mm) |
Frequently Asked Questions About Atomoxetine
No, atomoxetine is not a stimulant. It is a selective norepinephrine reuptake inhibitor (NRI), making it the first non-stimulant medication approved specifically for ADHD. Unlike stimulant medications such as methylphenidate (Ritalin) or amphetamines (Adderall), atomoxetine does not act primarily on dopamine pathways in the brain’s reward centers. Because of this, it has no significant potential for abuse or dependence and is not classified as a controlled substance in most countries. This makes it a valuable option for patients who cannot tolerate stimulants, have a history of substance abuse, or prefer a non-stimulant approach.
Unlike stimulant ADHD medications that begin working within 30 to 60 minutes, atomoxetine has a gradual onset of action. Some patients may notice initial improvements in attention and impulsivity within 1 to 2 weeks, but the full therapeutic effect is typically achieved after 4 to 6 weeks of consistent use at the target dose. This delayed onset is due to the time required for norepinephrine levels to stabilize in the brain. It is important to continue taking the medication as prescribed even if you do not feel an immediate benefit, and to communicate regularly with your doctor about your progress.
Yes, atomoxetine capsules can be taken with or without food. Food does not significantly affect the overall absorption of the medication. However, taking it with food may help reduce gastrointestinal side effects such as nausea and stomach upset, which are among the most common side effects, particularly during the first few weeks of treatment. If you experience persistent nausea, your doctor may also suggest splitting the daily dose into two administrations (morning and late afternoon).
Unlike some psychiatric medications (such as SSRIs or benzodiazepines), atomoxetine generally does not cause withdrawal symptoms when discontinued. However, stopping the medication will result in the return of ADHD symptoms. It is always advisable to discuss discontinuation with your doctor before stopping, as they may recommend a gradual dose reduction and can help you plan for managing ADHD symptoms through other strategies, such as behavioral therapy or alternative medications.
Atomoxetine is approved for use in children aged 6 years and older and has been extensively studied in pediatric clinical trials. It has demonstrated efficacy in reducing ADHD symptoms in children and adolescents. However, it does carry a regulatory warning (black box warning in the US) regarding an increased risk of suicidal thinking in children and adolescents, which occurs in approximately 0.4% of patients (compared to 0% on placebo in clinical trials). Close monitoring by parents and healthcare providers is essential, particularly during the first few months of treatment, when the dose is changed, or when behavioral changes are observed. Growth monitoring is also important, as some children may experience temporary effects on height and weight.
While there is no absolute contraindication to alcohol use with atomoxetine, caution is strongly advised. Both atomoxetine and alcohol can cause drowsiness, dizziness, and impaired concentration. Combining them may worsen these effects and increase the risk of accidents. Additionally, alcohol can exacerbate ADHD symptoms and may interfere with the therapeutic benefit of the medication. If you choose to consume alcohol, discuss the risks with your doctor and practice moderation.
References and Medical Sources
This article is based on the following peer-reviewed medical sources and regulatory documents. All medical information has been verified against current international guidelines and evidence-based medicine standards.
- European Medicines Agency (EMA). Strattera (atomoxetine) – Summary of Product Characteristics. EMA/CHMP. Available at: www.ema.europa.eu
- U.S. Food and Drug Administration (FDA). Strattera (atomoxetine hydrochloride) – Prescribing Information. FDA Reference ID. Available at: www.accessdata.fda.gov
- National Institute for Health and Care Excellence (NICE). Attention deficit hyperactivity disorder: diagnosis and management. NICE Guideline [NG87]. 2018, updated 2024. Available at: www.nice.org.uk/guidance/ng87
- British National Formulary (BNF). Atomoxetine monograph. Available at: bnf.nice.org.uk
- World Health Organization (WHO). International Classification of Diseases, 11th Revision (ICD-11): Attention deficit hyperactivity disorder (6A05). Available at: www.who.int
- Cortese S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry. 2018;5(9):727-738. doi:10.1016/S2215-0366(18)30269-4
- Michelson D, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108(5):E83.
- Adler LA, et al. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depression and Anxiety. 2009;26(3):212-221.
- Bangs ME, et al. Meta-analysis of suicidal ideation and suicidal behavior in pediatric patients treated with atomoxetine. Journal of the American Academy of Child & Adolescent Psychiatry. 2008;47(2):209-218.
- Childress AC, Sallee FR. Attention-deficit/hyperactivity disorder with inadequate response to stimulants: approaches to management. CNS Drugs. 2014;28(2):121-129.
Medical Editorial Team
This article has been written and reviewed by our team of medical professionals, ensuring accuracy and adherence to international clinical guidelines.
iMedic Medical Editorial Team – specialists in clinical pharmacology, psychiatry, and neurodevelopmental disorders. All content follows the GRADE evidence framework and is based on peer-reviewed research.
iMedic Medical Review Board – independent physicians who verify clinical accuracy, ensure adherence to EMA, FDA, and NICE guidelines, and confirm that information is current and evidence-based.
All medical content on iMedic is produced independently without pharmaceutical industry sponsorship or advertising. We follow strict evidence-based editorial standards based on international guidelines from the WHO, EMA, FDA, NICE, and the BNF. For more information, see our Editorial Standards.